Cite
HARVARD Citation
Lim, B. et al. (2021). A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2‐Negative Breast Cancer. Oncologist. pp. e230-e240. [Online].